# Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes

> **NCT05473806** · PHASE4 · UNKNOWN · sponsor: **Seung Up Kim** · enrollment: 28 (actual)

## Conditions studied

- Hepatitis B, Chronic
- Fibrosis, Liver
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Pioglitazone 15 Mg Oral Tablet
- **DRUG:** Evogliptin 5mg

## Key facts

- **NCT ID:** NCT05473806
- **Lead sponsor:** Seung Up Kim
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-18
- **Primary completion:** 2023-01-19
- **Final completion:** 2023-02-19
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05473806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05473806, "Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05473806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*